FDA Action Alert: Nabriva, Seattle Genetics, Sarepta and Nektar

FDA Action Alert: Nabriva, Seattle Genetics, Sarepta and Nektar

Pharm Exec’s 2019 Pipeline Report

Pharm Exec's 2019 Pipeline Report

Beat you to it, Kymriah: Gilead strikes discount Yescarta deal with NHS in adults

Beat you to it, Kymriah: Gilead strikes discount Yescarta deal with NHS in adults

AbbVie and Janssen announce failure of cancer drug in Phase 3 trial

AbbVie and Janssen have announced that Imbruvica (ibrutinib) failed to achieve the primary endpoint in a late-stage study assessing its use in patients with treatment-naïve diffuse large B-cell lymphoma, an aggressive form of non-Hodgkin lymphoma. The Phase 3 DBL3001 study found that Imbruvica did not improve event-free survival in previously untreated diffuse large B-cell lymphoma … Συνεχίστε να διαβάζετε AbbVie and Janssen announce failure of cancer drug in Phase 3 trial.